Physician
Berman, Ileana
Berman, Ileana was paid $3.22M by Medicaid between Jan 2018 and Nov 2024, across 20 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 42% of everything it billed.
33Billing provider infoBERMAN, ILEANA
ATTLEBORO, MA 02703
ATTLEBORO, MA 02703
33aNPI1245277961assigned 06/01/2006
33bProvider typePsychiatry Physician
28Total paid$3.22M
24GClaims52,522
24DCodes billed20
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Psychiatry Physician providers in Massachusetts
Rank by total paid#6 of 290
Median peer was paid$44K
This provider vs. median74×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,564 | $728K | |
| 2019 | 12,145 | $760K | |
| 2020 | 8,138 | $564K | |
| 2021 | 7,435 | $511K | |
| 2022 | 5,818 | $351K | |
| 2023 | 5,047 | $224K | |
| 2024incomplete | 2,375 | $86K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 42% | 28,964 | 18,246 | $1.37M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 37% | 13,514 | 9,243 | $1.19M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 15% | 5,388 | 4,637 | $491K |
| 90882 | 2.4% | 2,066 | 1,639 | $78K | |
| 99404 | 1.3% | 233 | 233 | $40K | |
| 90836 | <1% | 454 | 422 | $28K | |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | <1% | 92 | 92 | $9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 149 | 139 | $9K |
| 99205 | Prolong outpt/office vis | <1% | 29 | 29 | $5K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 51 | 32 | $2K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 13 | 13 | $454.35 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 123 | 106 | $0.00 |
8 more codes
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 250 | $0.00 |
| M1034 | Adults who have at least 180 days of continuous pharmacotherapy with a medication prescribed for oud without a gap of more than seven days | 0% | 170 | $0.00 |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 220 | $0.00 |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 47 | $0.00 |
| M1171 | Patient received at least one td vaccine or one tdap vaccine between nine years prior to the encounter and the end of the measurement period | 0% | 223 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 304 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 203 | $0.00 |
| M1168 | Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.